explore -WSS

explore

author：leisure time 2025-09-28 00:52:09 - browse：1514

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： A clever new way to fix Medicaid and graduate medical education

WSS

Abortion pill case raises question: who can sue the FDA?

Medicare solvency divides Republicans at the presidential debate

Covid vaccine financial winners and losers, from Pfizer to Novavax

Steward Health Care has deal to sell doctor network to UnitedHealth

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Vertex Pharmaceuticals may move headquarters in Boston

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

The cancer drug shortage isn’t new — and neither are the solutions

MoonLake credibility takes another hit with mid

Activists slam private health insurers over coverage restrictions

Why the world’s most expensive drug might be worth the price

Activists slam private health insurers over coverage restrictions

Medicare solvency divides Republicans at the presidential debate

What does generative AI mean for health care? We asked experts

Food as medicine: Medically tailored meals may get standardized

Psychedelics group wrestles with new pharma identity

Vertex Pharmaceuticals may move headquarters in Boston

hotspot

The Readout: Lenmeldy, GLP

Study: New antibiotic targets gonorrhea as well as last existing drug

Abortion clinic in Cancun will cater to Americans

Medicare will require more price transparency from hospitals

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

The Sacklers, horror, and ‘The Fall of the House of Usher’

hotspot

hotspot

knowledge

Wikipedia